Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ:SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with fibromyalgia and chronic pain as the initially targeted indications.
發育階段的迷幻生物技術 筒倉製藥 納斯達克股票代碼：SILO）已簽訂一項研發協議，研究和開發一種以纖維肌痛和慢性疼痛爲初始靶向適應症的劑量和延時釋放氯胺酮植入物。
The new project includes analytical testing and small batch, preclinical proof-of-concept trials to determine drug release and stability.
新項目包括分析測試和小批量臨床前概念驗證試驗，以確定藥物的釋放和穩定性。
CEO Eric Weisblum says the company is "beginning to explore" the option of treating fibromyalgia through ketamine-loaded implants, which would add to the existent R&D program of novel compound SP-26.
首席執行官埃裏克·韋斯布魯姆 表示，該公司正在 “開始探索” 通過裝有氯胺酮的植入物治療纖維肌痛的選擇，這將增加現有的新化合物 SP-26 的研發計劃。
The latter development is a time-released, dosage-controlled ketamine formulation of which positive results for pre-IND-enabling studies were recently announced, and for which Silo has filed a provisional patent application this past March.
後一項開發是一種定時發佈、劑量控制的氯胺酮配方，該配方最近宣佈了其促成前IND研究的積極結果，Silo已於去年3月爲此申請了臨時專利申請。
Weisblum believes the results from the new research will provide additional information and data for Silo's ongoing studies of ketamine treatments for fibromyalgia and other chronic pain conditions.
Weisblum認爲，這項新研究的結果將爲Silo正在進行的氯胺酮治療纖維肌痛和其他慢性疼痛疾病的研究提供更多信息和數據。
Fibromyalgia, a chronic condition causing generalized musculoskeletal pain as well as memory issues, sleep problems and fatigue affects about four million American adults -or about 2% of the total adult population.
纖維肌痛是一種導致全身性肌肉骨骼疼痛以及記憶問題、睡眠問題和疲勞的慢性疾病，影響着大約四百萬美國成年人，約佔成年人口總數的2％。
An analysis by Fortune Business Insights has estimated the treatment market for this condition is projected to grow at a CAGR of over 9% within the 2020-2027 period, while a more recent review by EMR calculated an expected 8.1% CAGR for the period spanning 2023-2031, achieving a $5.27 million global value by 2031.
的分析 《財富》商業洞察 估計，在2020-2027年期間，這種疾病的治療市場預計將以超過9％的複合年增長率增長，而EMR最近的一項審查計算，在2023-2031年期間，預計複合年增長率爲8.1％，到2031年全球價值將達到527萬美元。
See also: Wesana Shareholders Vote For Psilocybin And CBD Therapy Asset Sales To Lucy Scientific
另見：Wesana 股東投票支持向露西科學出售 psilocybin 和 CBD Therapy 資產
Silo is not alone in targeting fibromyalgia with psychedelic-assisted therapy. Tryp Therapeutics (OTC:TRYPF) is a patent-applied and in-progress psilocybin-based novel treatment.
Silo並不是唯一一個通過迷幻藥輔助療法靶向纖維肌痛的公司。Tryp Therapeutics（OTC: TRYPF）是一種已申請專利且正在進行中的基於psilocybin的新型療法。
Photo: Benzinga edit with photo by geralt on Pixabay and Wikimedia Commons.
照片：Benzinga 在 Pixabay 和維基共享資源上編輯了由 geralt 拍攝的照片。
譯文內容由第三人軟體翻譯。